Literature DB >> 23330955

Signaling by the phosphoinositide 3-kinase family in immune cells.

Klaus Okkenhaug1.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) control many important aspects of immune cell development, differentiation, and function. Mammals have eight PI3K catalytic subunits that are divided into three classes based on similarities in structure and function. Specific roles for the class I PI3Ks have been broadly investigated and are relatively well understood, as is the function of their corresponding phosphatases. More recently, specific roles for the class II and class III PI3Ks have emerged. Through vertebrate evolution and in parallel with the evolution of adaptive immunity, there has been a dramatic increase not only in the genes for PI3K subunits but also in genes for phosphatases that act on 3-phosphoinositides and in 3-phosphoinositide-binding proteins. Our understanding of the PI3Ks in immunity is guided by fundamental discoveries made in simpler model organisms as well as by appreciating new adaptations of this signaling module in mammals in general and in immune cells in particular.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23330955      PMCID: PMC4516760          DOI: 10.1146/annurev-immunol-032712-095946

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  235 in total

Review 1.  Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases.

Authors:  Nick R Leslie; Miles J Dixon; Martijn Schenning; Alex Gray; Ian H Batty
Journal:  Adv Biol Regul       Date:  2012-01

2.  AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species.

Authors:  Marisa M Juntilla; Vineet D Patil; Marco Calamito; Rohan P Joshi; Morris J Birnbaum; Gary A Koretzky
Journal:  Blood       Date:  2010-03-30       Impact factor: 22.113

3.  Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.

Authors:  Haiyan Wu; S Chandra Shekar; Rory J Flinn; Mirvat El-Sibai; Bijay S Jaiswal; K Ilker Sen; Vasantharajan Janakiraman; Somasekar Seshagiri; Gary J Gerfen; Mark E Girvin; Jonathan M Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

4.  Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction.

Authors:  Z Li; H Jiang; W Xie; Z Zhang; A V Smrcka; D Wu
Journal:  Science       Date:  2000-02-11       Impact factor: 47.728

5.  Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1.

Authors:  Eric V Dang; Joseph Barbi; Huang-Yu Yang; Dilini Jinasena; Hong Yu; Ying Zheng; Zachary Bordman; Juan Fu; Young Kim; Hung-Rong Yen; Weibo Luo; Karen Zeller; Larissa Shimoda; Suzanne L Topalian; Gregg L Semenza; Chi V Dang; Drew M Pardoll; Fan Pan
Journal:  Cell       Date:  2011-08-25       Impact factor: 41.582

Review 6.  Inhibitor and activator: dual functions for SHIP in immunity and cancer.

Authors:  William G Kerr
Journal:  Ann N Y Acad Sci       Date:  2010-12-13       Impact factor: 5.691

7.  Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction.

Authors:  Julia Rolf; Sarah E Bell; Dorottya Kovesdi; Michelle L Janas; Dalya R Soond; Louise M C Webb; Sara Santinelli; Ted Saunders; Barbara Hebeis; Nigel Killeen; Klaus Okkenhaug; Martin Turner
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

8.  The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.

Authors:  Faruk Ramadani; Daniel J Bolland; Fabien Garcon; Juliet L Emery; Bart Vanhaesebroeck; Anne E Corcoran; Klaus Okkenhaug
Journal:  Sci Signal       Date:  2010-08-10       Impact factor: 8.192

9.  PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ.

Authors:  Yutaka Kurebayashi; Shigenori Nagai; Ai Ikejiri; Masashi Ohtani; Kenji Ichiyama; Yukiko Baba; Taketo Yamada; Shohei Egami; Takayuki Hoshii; Atsushi Hirao; Satoshi Matsuda; Shigeo Koyasu
Journal:  Cell Rep       Date:  2012-03-29       Impact factor: 9.423

Review 10.  Myotubularin phosphoinositide phosphatases: cellular functions and disease pathophysiology.

Authors:  Karim Hnia; Ilaria Vaccari; Alessandra Bolino; Jocelyn Laporte
Journal:  Trends Mol Med       Date:  2012-05-11       Impact factor: 11.951

View more
  154 in total

Review 1.  Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Authors:  Bart Vanhaesebroeck; Maria A Whitehead; Roberto Piñeiro
Journal:  J Mol Med (Berl)       Date:  2015-12-10       Impact factor: 4.599

2.  Ncking BCR-mediated PI3K activation.

Authors:  Jennifer L Cannons; Fang Zhao; Pamela L Schwartzberg
Journal:  EMBO Rep       Date:  2013-08-23       Impact factor: 8.807

3.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Authors:  Gulidanna Shayan; Raghvendra Srivastava; Jing Li; Nicole Schmitt; Lawrence P Kane; Robert L Ferris
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

4.  Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Matthew Lunning; Julie Vose; Loretta Nastoupil; Nathan Fowler; Jan A Burger; William G Wierda; Marshall T Schreeder; Tanya Siddiqi; Christopher R Flowers; Jonathon B Cohen; Peter Sportelli; Hari P Miskin; Michael S Weiss; Susan O'Brien
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

5.  Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Stacey Tannheimer; Amy J Johnson; Shuai Dong; Anne-Katrien Stark; Klaus Okkenhaug; Angela Panoskaltsis-Mortari; Peter T Sage; Arlene H Sharpe; Leo Luznik; Jerome Ritz; Robert J Soiffer; Corey S Cutler; John Koreth; Joseph H Antin; David B Miklos; Kelli P MacDonald; Geoffrey R Hill; Ivan Maillard; Jonathan S Serody; William J Murphy; David H Munn; Colby Feser; Michael Zaiken; Bart Vanhaesebroeck; Laurence A Turka; John C Byrd; Bruce R Blazar
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

Review 6.  Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect.

Authors:  Stuart G Tangye; Julia Bier; Anthony Lau; Tina Nguyen; Gulbu Uzel; Elissa K Deenick
Journal:  J Clin Immunol       Date:  2019-03-25       Impact factor: 8.317

Review 7.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

8.  Macrophage Phosphoproteome Analysis Reveals MINCLE-dependent and -independent Mycobacterial Cord Factor Signaling.

Authors:  Madlen Hansen; Julian Peltier; Barbara Killy; Bushra Amin; Barbara Bodendorfer; Anetta Härtlova; Sebastian Uebel; Markus Bosmann; Jörg Hofmann; Christian Büttner; Arif B Ekici; Mario Kuttke; Henrik Franzyk; Camilla Foged; Sandra Beer-Hammer; Gernot Schabbauer; Matthias Trost; Roland Lang
Journal:  Mol Cell Proteomics       Date:  2019-01-11       Impact factor: 5.911

9.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

10.  Phosphoinositide 3-Kinase Is Involved in Mediating the Anti-inflammation Effects of Vasopressin.

Authors:  Woan-Ching Jan; Ming-Chang Kao; Chen-Hsien Yang; Ya-Ying Chang; Chun-Jen Huang
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.